Drugs / WT1 126-134 peptide
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00433745 | Feb 2007 → Nov 2009 | acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndrome | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 2 | NCT00153608 | Apr 2004 → ? | cancer or benign tumor | Charite University, Berlin, Germany | Unknown | No outcome recorded |
| Phase 2 | NCT00153582 | Apr 2002 → ? | acute myeloid leukemia, myelodysplastic syndrome | Charite University, Berlin, Germany | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WT1 126-134 peptide | “WT1 vaccination (9 doses of WT-1:126-134 peptide (in Montanide adjuvant) administered concomitantly with GM-CSF (Sargramostim)” NCT00433745 ↗ |
| Modality | Peptide | “vaccinated with a peptide from the leukemia-associated antigen WT1” NCT00153582 ↗ |
| Target | WT1 | “Wilm's Tumor 1 (WT1) was identified as a target vaccine antigen” NCT00433745 ↗ |